Result: Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial

*Title*:

*Author/editor-in-chief*:

*Published in*:

eClinicalMedicine. - Amsterdam : Elsevier, 04.10.2023. - 10.1016/j.eclinm.2023.102237. - ISSN 2589-5370. - Jahrgang 65, Artikel 102237

*Publication*:

Amsterdam : Elsevier, 04.10.2023

*Distribution*:

Frankfurt am Main : Universitätsbibliothek Johann Christian Senckenberg

*Physical description scale*:

1 Online-Ressource (12 Seiten)

*Format*:

*eBook*

*Language*:

*eng*

*DOI*:

10.1016/j.eclinm.2023.102237

*oa_rights*:

Open Access
CC BY-NC-ND 4.0

*Result*: Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial